Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Palatin Technologies reports revenue challenges but advances pipeline programs

Palatin Technologies faced revenue challenges in Q3 2024 but showcased strengths in pipeline advancements and positive clinical results.
The company's financial performance improved despite increased operating expenses, with a focus on expanding clinical programs and enhancing drug profiles.
While facing cash utilization concerns and upcoming study expenses, Palatin remains optimistic about its progress and future milestones.

Palatin Technologies reports Q4 loss, progresses in ocular treatments

Palatin Technologies navigated Q4 2024 with a focus on cost reduction and asset sales, impacting revenue and expenses.
Despite financial challenges, the company's progress in ocular programs and pipeline development showcases strategic advancements.
Opportunities lie in leveraging asset sale proceeds, advancing clinical programs, and addressing funding needs for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Topline data currently expected late 4Q calendar 2023 Interim analysis of first 120 patients demonstrated: Excellent safety and tolerability product profile  Potential for PL9643 to address multiple signs and symptoms of dry eye disease  CRANBURY, N.J. , Sept. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that enrollment in the PL9643 MELODY-1 Phase 3 study in dry eye disease (DED) is complete, with 570 patients enrolled.

Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease

~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated bremelanotide with a PDE5i Phase 2 clinical study in PDE5i non-responder ED patients currently expected to commence in 4Q 2023  CRANBURY, N.J. , Aug. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has initiated a clinical development program evaluating bremelanotide, a melanocortin receptor 4 (MCR4) agonist, co-formulated with a PDE5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy.

Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment

First prescription dispensed in Chinese Hainan Province 93% of patients enrolled completed the Phase 3 trial in premenopausal patients with Hypoactive Sexual Desire Disorder (HSDD) in South Korea Data expected later this year Supports submission to Korean Ministry of Food & Drug Safety (MFDS) for Marketing Approval CRANBURY, N.J. , Aug. 8, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that Fosun Pharma, the licensee of Vyleesi in China, reported its first sale in the Hainan Province of China.

Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's Women's Health Platform CRANBURY, N.J. , Aug. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered a strategic partnership with UpScriptHealth, a leading direct-to-consumer telemedicine company providing telemedicine services to pharmaceutical and medical technology companies.

Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®

CRANBURY, N.J. , Aug. 4, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 5:00 p.m.

Palatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference

$4.1 million in Gross Product Revenue 20% growth over 3Q23; 78% growth over 4Q22 $1.7 million in Net Product Revenue 42% growth over 3Q23; 122% growth over 4Q22 14% growth in prescriptions dispensed over 3Q23; 89% growth over 4Q22 6 consecutive quarters of double-digit growth 20% growth in new healthcare prescribers over 3Q23 CRANBURY, N.J. , July 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced preliminary fiscal fourth quarter ended June 30, 2023 Vyleesi® product revenue results.

Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results

–  Results demonstrate melanocortin agonists may represent a new therapeuticavenue to treat diabetic nephropathy –  Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J. , May 30, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of the poster "MC1R Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced Rat Model of Diabetic Nephropathy" at the International Podocyte Conference May 24-26, 2023 in Philadelphia, PA.

Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference

Palatin Technologies, Inc. (NYSE:PTN ) Q3 2023 Earnings Conference Call May 16, 2023 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Higgins - Ladenburg Thalmann Operator Greetings.

Palatin Technologies, Inc. (PTN) Q3 2023 Earnings Call Transcript

Palatin Technologies, Inc. (PTN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.75 per share a year ago.

Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates

Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Analysis of Lead-In Population of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye along with Excellent Patient Safety and Tolerability Final Data Expected Second Half Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis  Interim Analysis Targeted for Second Half Calendar Year 2023  Topline Results Currently Expected First Half Calendar Year 2024 Vyleesi® Net Product Revenue Increased 16% Over the Prior Quarter Prescriptions Dispensed Increased 27% Over the Prior Quarter 5 Consecutive Quarters of Double-Digit Growth Received $4.7 Million of Non-Dilutive Funding Through NJ Economic Development Program Teleconference and Webcast to be held on May 16, 2023, at 11:00 AM ET CRANBURY, N.J. , May 16, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2023.

Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

CRANBURY, N.J. , May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets.

Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

–  Preclinical data presented shows PL8177 was found to be efficacious in animal models of inflammatory bowel disease –  Clinical data confirms PL8177 oral formulation is delivered and contained in the colon –  Phase 2 clinical study data readout in 2H2023 CRANBURY, N.J. , May 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of the poster "Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases" at the Digestive Disease Week annual meeting May 6-9, 2023 in Chicago, Illinois.

Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

CRANBURY, N.J. , May 8, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today hosted a key opinion leader (KOL) webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase 3 clinical trial for Dry Eye Disease.

Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar

- Review of Phase 3 PL9643 Data for Dry Eye Disease - Data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease - Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET CRANBURY, N.J. , May 1, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a key opinion leader (KOL) webinar on May 8, 2023 at 11:00 a.m.

Palatin Technologies to Host Key Opinion Leader Webinar

- Poster data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease - Consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating product profile - Melody-1 Phase 3 clinical study continuing patient enrollment - final data second half of 2023 CRANBURY, N.J. , April 27, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of a poster entitled Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease: Results From 2 Independent Clinical Trials at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference.

Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference

-  Poster presented at ARVO demonstrates PL9588 reduces intraocular pressure -  Data provides further support for topical administration of melanocortins for ocular inflammation CRANBURY, N.J. , April 25, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of a poster entitled, Melanocortin Receptor Agonist PL9588 Reduces Intraocular Pressure in Normotensive Rabbits at the Association of Research in Vision and Ophthalmology (ARVO) Annual Conference.

Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma

$3.4 million in Gross Product Revenue 31% growth over 2Q23; 165% growth over 3Q22 $1.2 million in Net Product Revenue 22% growth over 2Q23; 469% growth over 3Q22 27% growth in prescriptions dispensed over 2Q23; 147% growth over 3Q22 5 consecutive quarters of double-digit growth CRANBURY, N.J. , April 19, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced preliminary fiscal third quarter ended March 31, 2023 Vyleesi® product revenue results.

Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results

Planet Based Foods Global Inc. (CSE: PBF) (OTCQB: PBFFF) (FRA: AZ0) ("PBFG," "Planet Based Foods" or the "Company") is pleased to announce that the Company has entered into a non-exclusive development agreement ("Development Agreement") with renowned global producer, DoehlerGroup ("Doehler"). The objective of the Development Agreement is to establish a commercial relationship between Planet Based Foods and Doehler, with the intention to work towards a formal production agreement.

Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences

Oral PL8177 is gut restricted in rats, dogs and humans Bioinformatics data shows positive effects on enterocytes and infiltrating immune cells CRANBURY, N.J. , March 2, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers in Immunology published a manuscript, "A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs and humans," summarizing data demonstrating oral PL8177 provides therapeutic effects in inflammatory bowel disease and pharmacokinetic data from a clinical study showing PL8177 remains restricted to the gut.

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease

Palatin Technologies, Inc. (NYSE:PTN ) Q1 2023 Earnings Conference Call February 15, 2023 11:00 AM ET Company Participants Carl Spana - President and CEO Steve Wills - EVP, CFO and COO Conference Call Participants Joe Pantginis - H.C. Wainwright Farhana Sakloth - Ladenburg Thalmann John Newman - Canaccord Genuity Operator Greetings.

Palatin Technologies, Inc. (PTN) Q1 2023 Earnings Call Transcript

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results Currently Expected Mid-Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced First Patient Dosed Planned Interim Analysis Targeted for First Half Calendar Year 2023 Topline Results Currently Expected Second Half Calendar Year 2023 Phase 2 Clinical Study of Bremelanotide in Patients with Diabetic Kidney Disease  Complete Enrollment Targeted for Third Quarter Calendar Year 2023 Topline Results Currently Expected First Quarter Calendar Year 2024 Vyleesi® - Net Product Revenue Increased 18% and Prescriptions Dispensed Increased 12% Over the Prior Quarter Closed on a $10.0 Million Registered Direct Offering Received $4.7 Million of Non-Dilutive Funding Through NJ Economic Development Program Teleconference and Webcast to be held on February 15, 2023, at 11:00 AM ET CRANBURY, N.J. , Feb. 15, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2022.

Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

CRANBURY, N.J. , Feb. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, before the open of the U.S. financial markets.

Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023

-  BREAKOUT Study is Palatin's third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists -  Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J. , Jan. 19, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2b clinical trial with the melanocortin agonist, bremelanotide.

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Sells Net Operating Loss Tax Benefits Through New Jersey Economic Development Program CRANBURY, N.J. , Jan. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has received approximately $4.7 million of non-dilutive funding through the New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program.

Palatin Receives $4.7 Million of Non-Dilutive Funding

-  Collaboration with The William Harvey Research Institute and Queen Mary University of London -  PL-8177 displayed pro-resolving and anti-arthritic effects in rodents CRANBURY, N.J. , Jan. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers in Immunology published a manuscript, "Pro-resolving and anti-arthritic Properties of the MC1 Selective Agonist PL8177",  summarizing data demonstrating PL8177 provides therapeutic effects in inflammatory conditions, including arthritis.

News for Palatin Technologies Stock (PTN)